Truist lowered the firm’s price target on Cognex (CGNX) to $37 from $43 and keeps a Hold rating on the shares. The company’s Q4 results topped EPS estimates by 25% on better sales and profit, but its Q1 guide and what’s implied for FY25 suggest that consensus estimates were too high, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGNX:
- Cognex: Buy Rating Amidst Challenges and Opportunities with Strong Logistics Growth and AI Advancements
- Cognex Sees Strong Q4 Results Amidst Sector Challenges
- Cognex’s Strong Q4 Performance and Strategic Expansion Justify Buy Rating, Despite Early 2025 Challenges
- Cognex reports Q4 adjusted EPS 20c, consensus 16c
- Cognex sees Q1 revenue $200M-$220M, consensus $227.22M